Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.52 |
| ▸ | CMA1 | P23946 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021917 | 0.90 | ACE (0.56) | ACEKLK5F2PRSS1ACE2 | |
| SCHEMBL17081787 | 0.90 | ACE (0.56) | ACEKLK5F2PRSS1ACE2 | |
| SCHEMBL10053455 | 0.90 | ACE (0.56) | ACEKLK5F2PRSS1ACE2 | |
| SCHEMBL7321218 | 0.89 | ACE (0.60) | ACEKLK5F2PRSS1ACE2 | |
| SCHEMBL28002546 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL12658455 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7268512 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL28002552 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL8365663 | 0.86 | ACE (0.56) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL3692085 | 0.85 | ACE (0.77) | ACEKLK5F2PRSS1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | NGLY1, CRH, NPY1R | ACE 842/4885KLK5 3017/4885F2 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.